<DOC>
	<DOCNO>NCT00796133</DOCNO>
	<brief_summary>This Phase 2 , dose-finding , cross-over study purpose evaluate effect NES/E2 transdermal gel delivery ovulation suppression normal ovulate woman .</brief_summary>
	<brief_title>A Phase 2 , Dose-finding , Cross-over Study Evaluate Effect NES/E2 Transdermal Gel Delivery Ovulation Suppression Normal Ovulating Women</brief_title>
	<detailed_description />
	<criteria>Woman 18 40 year age Has intact uterus ovary Has regular menstrual cycle 2535 day duration Able comply protocol , include frequent blood sampling , live within catchment area clinic Understands study procedure agree participate study give write informed consent Able use nonhormonal , doublebarrier contraceptive ( e.g . condom diaphragm ) every act intercourse , sterilize tubal ligation , male partner sterilize vasectomy Progesterone &gt; 10 nmol/L least one sample leadin cycle All contraindication OC use include Thrombophlebitis thromboembolic disorder Past history deep vein thrombophlebitis thromboembolic disorder Past current cerebrovascular coronary artery disease Known suspect carcinoma breast Carcinoma endometrium know suspected estrogendependent neoplasia Undiagnosed abnormal genital bleeding Cholestatic jaundice pregnancy jaundice prior pill use Hepatic adenoma carcinoma Woman history headache focal neurological symptom Known suspected pregnancy Aged &gt; 35 smoker BMI &gt; 29 Positive urine pregnancy test screen baseline visit Desired pregnancy within duration study Known hypersensitivity progestin Known hypersensitivity estrogen Undiagnosed vaginal discharge vaginal lesion abnormality In accordance Bethesda system classification Women current abnormal Pap smear suggestive highgrade pre cancerous lesion ( ) , include HGSIL , exclude Women LGSIL ASCUS/highrisk HPV positive may participate evaluate colposcopy biopsy evidence lesion severity &gt; CIN I present and/or endocervical curettage negative Women biopsy find CIN I follow find per standard care ; woman exclude treatment indicate In accordance Pap class system Women high grade dysplasia exclude Women low grade dysplasia CIN I interpretation Pap smear may participate base investigator discretion accordance local standard care Breastfeeding Cancer ( past history carcinoma sarcoma ) History significant psychiatric disorder , include severe depression . Chronic acute liver renal disease Hypertension control medication define diastolic BP 85 mm Hg systolic BP 135mm Hg 15 minute rest Dermatitis , psoriasis severe skin disorder Known suspect alcoholism drug abuse Clinically significant abnormality laboratory safety test Chronic disease history illness , opinion investigator , might confound result study pose additional risk subject Woman participate participate another clinical study ( involve investigational drug ) within one month prior enrollment . Use injectable contraceptive previous 3 month ( e.g . cyclofem ) 9 month ( e.g . DMPA ) Use oral contraceptive within past 1 month Use concomitant drug may interact study drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>NES/E2</keyword>
	<keyword>transdermal gel delivery</keyword>
	<keyword>contraception</keyword>
	<keyword>ovulation</keyword>
	<keyword>bleeding pattern</keyword>
</DOC>